Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Novel Findings Presented By Pitt Melanoma Researchers At ASCO
Researchers from the University of Pittsburgh Cancer Institute (UPCI) have identified eight genes that help predict a melanoma patient"s response to treatment. The new findings are being presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO), May 29 to June 2, in Orlando, Fla. Don't forget to buy zoloft online no prescription.

Mapping Gene Expression With Gene Expression Atlas
Recently, researchers at the European Molecular Biology Laboratory"s European Bioinformatics Institute (EMBL-EBI) launched a new database, the Gene Expression Atlas, which allows scientists to search and compare gene expression data at unprecedented detail and scope. Observing how gene expression varies in different cell types, tissues and under disease conditions can help researchers understand gene function and to develop new drugs and therapies.

generic viagra online


News of the day
Amyloid Aggregations And Tau Pathology Reflected By Cortical Thickness In The Default Network Of MCI And AD
Alzheimer"s disease patients show a relentless decline in memory over the course of the disease, which is accompanied by both brain atrophy and by characteristic deposits in the brain tissue called amyloid plaques and neurofibrillary tangles. Researchers from the Chinese Academy of Sciences studied a large database, collected in the US, of patients with Alzheimer"s or memory complaints who had MRI scans and had spinal taps to collect cerebrospinal fluid, which is in the brain and spinal chord. By examining the CFS they could measure the amounts of the substances that make p plaques and tangles, and related this to brain atrophy. They found that the amount of plaque and tangle-producing chemicals in the cerebrospinal fluid correlated with brain tissue loss in selective regions of the brain which are typically affected in Alzheimer"s disease. The brains in these regions had thinned out suggesting that brain cells had died. These regions are important for memory and are typically active when the brain is at rest. Using these techniques may ultimately help identify early markers of disease in Alzheimer"s, potentially indicating who is likely to develop Alzheimer"s before memory loss is critical.
Health Insurance

Data Published In The New England Journal Of Medicine Support Use Of Raxibacumab (ABthrax(TM)) For The Treatment Of Inhalation Anthrax

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced publication by The New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company"s human monoclonal antibody drug raxibacumab (ABthrax(TM)), as well as the results of human safety studies, which supported the use of raxibacumab in the event of life-threatening inhalation anthrax disease. "The results published showed that a single dose of raxibacumab was highly effective as a treatment for inhalation anthrax in both rabbits and monkeys," said Sally D. Bolmer, Ph.D., R.A.C, lead author and Senior Vice President, Development and Regulatory Affairs, HGS. "Raxibacumab acted quickly to provide a significant survival benefit to animals showing clinical signs of disease caused by exposure to a dose of aerosolized anthrax spores that was approximately 200 times the median lethal dose. We also note that the safety profile shown in healthy human volunteers provides support for use of raxibacumab in the clinical setting of immediately life-threatening inhalation anthrax disease." Raxibacumab represents a new way to address the anthrax threat. While antibiotics can kill the anthrax bacteria, they are not effective against the deadly toxins that the bacteria produce. Raxibacumab targets anthrax toxins after they are released by the bacteria into the blood and tissues. In an inhalation anthrax attack, people may not know they are infected with anthrax until the toxins already are circulating in their blood, and it may be too late for antibiotics alone to be effective. "We are very proud that the importance of these data and the rigor and high quality of our scientists" work have led to publication in The New England Journal of Medicine," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "Based on these results, we believe raxibacumab has the potential to be a significant step forward in the treatment of inhalation anthrax." About the Raxibacumab Contract with the U.S. Government Raxibacumab is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS). In April 2009, HGS fulfilled its commitment to deliver the first 20,000 doses of raxibacumab to the Strategic National Stockpile for emergency use in the treatment of inhalation anthrax. The purchase was made under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures. In May 2009, HGS submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for raxibacumab for the treatment of inhalation anthrax. The BLA was also filed under the BARDA contract, and HGS will receive $10 million from the U.S. Government upon FDA licensure of raxibacumab. About Anthrax Anthrax infection is caused by a spore-forming bacterium, Bacillus anthracis, which multiplies in the body and produces lethal toxins. Most anthrax fatalities are caused by the irreversible effects of the anthrax toxins. Research has shown that the bacteria produce protective antigen, the key facilitator in the progression of anthrax infection at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. Raxibacumab blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells. About Human Genome Sciences The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company"s primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. Albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are ongoing, with results expected in July and November 2009. In April 2009, HGS completed delivery of 20,000 doses of raxibacumab (ABthrax(TM)) to the U.S. Strategic National Stockpile for use in an emergency for the treatment of inhalation anthrax. The Company also has several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglutide), currently in Phase 3 development as a potential treatment for type 2 diabetes. Human Genome Sciences, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009